Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 7Phase 1/2 6Phase 1 5

Status

Active not recruiting 3Terminated 2Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 8INDUSTRY 8NETWORK 2NIH 1

Study Type

Interventional 8

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × amivantamab × Clear all
NCT05498428 2026-06-05

PALOMA-2

Janssen Research & Development, LLC

Phase 2 Recruiting
520 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-06-05

COCOON

Janssen Research & Development, LLC

Phase 2 Active not recruiting
305 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-06-05

COPERNICUS

Janssen Research & Development, LLC

Phase 2 Recruiting
480 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Janssen Research & Development, LLC

Phase 2 Active not recruiting
68 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07586202 2026-05-14

AmiNA

Janssen Research & Development, LLC

Phase 2 Not yet recruiting
68 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

AstraZeneca

Phase 2 Active not recruiting
60 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05653427 2025-01-13

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Janssen Research & Development, LLC

Phase 2 Terminated
18 enrolled 20 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT04945733 2024-09-19

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Janssen Pharmaceutical K.K.

Phase 2 Terminated
62 enrolled 28 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡